AbbVie Inc (ABBV) is a publicly traded drug manufacturers-general business based in the US. It opened the day at $158.83 after a previous close of $157.58. During the day the price has varied from a low of $157.375 to a high of $159.14. The latest price was $157.54 (25 minute delay). AbbVie is listed on the NYSE and employs 50,000 staff. All prices are listed in US Dollars.
Best for
0% commission
BEST FOR
Welcome Bonus
Best for
Beginner investments
Best for
Beginners
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Customer rating | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|---|
|
★★★★★ | £0 | £1 | £2.88 £642.65 total |
Capital at risk |
|
★★★★★ | £0 | $50 | £3.20 £642.97 total |
Capital at risk |
|
★★★★★ | £0 | £250 | £11.36 £651.13 total |
Capital at risk |
|
Not yet rated | £0 | No minimum | £3.20 £642.97 total |
Capital at risk |
 |
★★★★★ | £0 | No minimum | £6.40 £646.17 total |
Capital at risk |
 |
★★★★★ | £0 | £1 | £18.35 £658.12 total |
Capital at risk |
 |
★★★★★ | £0 | £0.01 | £0.64 £640.41 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Only you can make the decision on the time to leap. The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the AbbVie P/E ratio, PEG ratio and EBITDA
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, AbbVie shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, AbbVie's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2788. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider AbbVie's PEG ratio in relation to those of similar companies.
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $31.1 billion (£25.3 billion).
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.
AbbVie's total ESG risk: 34.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 01/01/2019) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare AbbVie's total ESG risk score against those of similar companies.
AbbVie's environmental score: 4.96/100
AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
AbbVie's social score: 22.65/100
AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
AbbVie's governance score: 16.25/100
AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
AbbVie's controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.
Wondering how that compares? Below are the controversy scores of similar companies.
Join 50,000 subscribers who are notified about expert money tips. Plus a chance to win £500!
By signing up you agree to receive emails from Finder and to the privacy policy and terms & conditions.
In May 2020, AbbVie completed its acquisition of Allergan plc. It's no longer possible to buy shares in Allergan, but you can invest in AbbVie. Just bear in mind that you'd be investing in all areas of AbbVie's operations – not just the newly-annexed Allergan operations.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Blue Water Vaccines? We explain how and compare a range of providers that can give you access to many brands, including Blue Water Vaccines.
Ever wondered how to buy shares in Veru? We explain how and compare a range of providers that can give you access to many brands, including Veru.
Ever wondered how to buy shares in C4 Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including C4 Therapeutics.
Ever wondered how to buy shares in Clever Leaves? We explain how and compare a range of providers that can give you access to many brands, including Clever Leaves.
Ever wondered how to buy shares in NeuroSense Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including NeuroSense Therapeutics.
Mental health stocks can be rewarding, but there are risks involved that could impact your profits. Find out how to invest in companies in the mental health industry.
Pharma stocks can be rewarding, but there are risks involved that could impact your profits. Find out the best way to invest in pharma stock.
Ever wondered how to buy shares in Bone Biologics? We explain how and compare a range of providers that can give you access to many brands, including Bone Biologics.
Ever wondered how to buy shares in Adagio Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Adagio.
Ever wondered how to buy shares in Bolt Biotherapeutics? We explain how and compare a range of providers that can give you access to many brands, including Bolt Biotherapeutics.
